{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":21,"n_cols":5,"rows_kept":21,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[4,2,4,3],[5,2,5,3],[6,2,6,3],[7,2,7,3],[8,2,8,3],[9,2,9,3],[15,2,15,3],[16,2,16,3],[19,2,19,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910456904903321"]
[null,null,"Titolo",null,"Nursing I.V. drug handbook / / editors, Lynne Christensen, Holly Clark, Rita M. Doyle"]
[null,null,"Pubbl/distr/stampa",null,"Philadelphia : , : Lippincott Williams & Wilkins, , [2006]"]
[{"$nulls":4},"©2006"]
[null,null,"ISBN",null,"1-4698-8624-3"]
[null,null,"Edizione",null,"[Ninth edition.]"]
[null,null,"Descrizione fisica",null,"1 online resource (831 p.)"]
[null,null,"Collana",null,"Nursing I.V. drug handbook, , 1040-2373"]
[null,null,"Disciplina",null,"615.5/8"]
[null,null,"Soggetti",null,"Nursing"]
[{"$nulls":4},"Intravenous therapy"]
[{"$nulls":4},"Drugs"]
[{"$nulls":4},"Drugs - Physiological effect"]
[{"$nulls":4},"Drugs - Administration"]
[{"$nulls":4},"Electronic books."]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Includes index."]
[null,null,"Nota di contenuto",null,"\"\"I.V. DRUG\"\"; \"\"CONTENTS\"\"; \"\"CONTRIBUTORS AND CONSULTANTS\"\"; \"\"HOW TO USE NURSING I.V. DRUG HANDBOOK\"\"; \"\"GUIDE TO ABBREVIATIONS\"\"; \"\"I.V. Drugs, Solutions, and Blood Products Alphabetized entries\"\"; \"\"APPENDICES AND INDEX\"\"; \"\"RISKS OF CENTRAL I.V. THERAPY\"\"; \"\"RISKS OF PERIPHERAL I.V. THERAPY\"\"; \"\"THERAPEUTIC MONITORING GUIDELINES FOR I.V. DRUGS\"\"; \"\"MAJOR ELECTROLYTE COMPONENTS OF I.V. SOLUTIONS\"\"; \"\"PREVENTING AND TREATING EXTRAVASATION\"\"; \"\"GUIDELINES FOR HANDLING CHEMOTHERAPEUTIC DRUGS\"\"; \"\"CANCER CHEMOTHERAPY: ACRONYMS AND PROTOCOLS\"\""]
[{"$nulls":4},"\"\"SELECTED DRUGS FOR CONSCIOUS SEDATION IN ADULTS\"\"\"\"DIALYZABLE DRUGS\"\"; \"\"UNDERSTANDING CONTROLLED SUBSTANCE SCHEDULES\"\"; \"\"RATING PREGNANCY RISK\"\"; \"\"OSMOLALITY, OSMOLARITY, AND pH\"\"; \"\"BLOOD TYPE COMPATIBILITY\"\"; \"\"I.V. DRUG COMPATIBILITY\"\"; \"\"INDEX\"\""]